Enrollment Begins in Phase 2 Trial of Rintatolimod in PD-1/PD-L1 Resistant Melanoma
Source: Targeted Oncology, September 2022
Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.
A phase 2 study examining a polarized dendritic cell (aDC1) vaccine in combination with interferon alpha-2b, rintatolimod (ampligen), and celecoxib (Celebrex), in patients with primary PD-1/PD-L1 resistant melanoma has begun enrolling patients, according to AIM ImmunoTech Inc.
“The start of this NCI-funded clinical trial marks an important milestone for our Melanoma R&D program. Despite recent successes of immune checkpoint inhibitors in advanced-stage disease, only a minority of treated melanoma patients have a durable benefit, reinforcing the need to develop second-line therapies that are effective against checkpoint-refractory disease,” said Thomas K. Equels, chief executive officer of AIM ImmunoTech Inc, in the press release. “Based on the data seen to-date, we believe Ampligen, in combination with Roswell’s polarized dendritic cell vaccine plus interferon, has an opportunity to fill this gap and potentially provide clinical benefit to melanoma patients in need.”